The End of Heart Disease in a SINGLE Dose?

An explanation of how cholesterol-containing lipoproteins contribute to atherosclerotic cardiovascular disease, including plaque buildup and the clinical reliance on treatments like statins and PCSK9 inhibitors to manage these levels.

Discussion of the PISA study and Mendelian randomization trials, which provide strong evidence that lower levels of cholesterol-containing lipoproteins are directly associated with reduced risks of plaque-related heart disease.

An analysis of the phase one trial for VERVE 102, a gene therapy that utilizes CRISPR Cas9 to inactivate the PCSK9 gene. This single-dose treatment showed a 60% reduction in LDL cholesterol with potentially life-long effects.

A critical examination of the irreversible nature of gene therapy. While the reduction in cholesterol is impressive, the permanent alteration of one's genetics raises concerns about long-term off-target effects and the lack of a 'rewind' button for patient health.